The markets are dancing with glee over Erbitux, the ImClone/Bristol-Myers cancer drug. ImClone and Bristol-Myers share prices both surged on news that the drug improved the survival rates of non-small cell lung cancer patients in a late-stage trial.
Shares in ImClone's European partner Merck KGaA also rose on the news, as analysts boosted predictions for European sales to $1.4 billion from $1.1 billion. The drug is already approved for sale in the U.S. and Europe for treatment of colon cancer, and head and neck cancer.
This new lung-cancer trial added Erbitux to a common European chemo regimen that includes vinorelbine and cisplatin. Two months ago, a similar-but-separate trial that combined Erbitux with taxane and carboplatin--two drugs commonly used in the U.S.--failed.
- check out ImClone's release
- see this report from MarketPlace
ImClone names new CEO. Report
ImClone shares dive after Erbitux fails a Phase III. Report
Erbitux data underscores leaked disappointment. Report
ImClone buoyed by new Erbitux data. Report
ImClone touts survival rate in Erbitux cancer trial. Report